Indication intelligence, analysis and sector perception

The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?

September 17, 2021

When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response! Being able to trade a stock doesn't mean it is worth the share price; an equity that has WHAT is BSTG’s value proposition, after all the share price pumping there is NO clinical trial initiation after a year and a half (1.5 years)? <read more)

The Biostage (BSTG) Chronicles: Facts from filed 10-Q

August 20, 2021

What’s true, false, misleading, unresolved and unanswered issues with SLOPPY if any follow-through to date? Critical issue:  still subject to “Going Concern” label due to lack of financing, low cash position and “runway” HUGE deficit to date:  $70.2 million with NO clinical TRIAL initiation with a year and a one-half old approved IND … it’s NOT about COVID stoppage, there are NOT any clinical employees left and NO monies to initiate?

Q2/21 Earnings - (LPS - loss-per-share) Results

August 16, 2021

A scorecard of of 35 covered  companies and date of releases (to date). The current LPS (loss per share) or net income, cash positions i.e. "runways"  is a reflection of this universe's investing "status" Reported to today ... with a LPS (loss-per-share) tag - Athersys (ATHX), bluebird bio (BLUE), Precigen (PGEN), Regenxbio (RGNX), Voyager Therapeutics (VYGR), BioLife Solutions (BLFS), Bellicum Pharmaceuticals (BLCM), Homology Medicine (FIXX), Chinook Therapeutics (KDNY), Biostage (BSTG), Solid Biosciences (SLDB) to date